Use of „EUCARBON“ for the treatment of patients suffering from irritable bowel syndrome and from constipation. Group of patients:
Allochol, Zantac, Enap-H., Ursosan, Librax, Conclusion
The efficacy of “Eucarbon” was investigated Lansoprasol, Anafranil. on a group with 35 patients. From this group 8 patients were cigarette smokers, 6 from So, after “Eucarbon” therapy we can con-18 were men and 17 women. The average age them were smoking 10 cigarettes a day, the 2 clude:was 45,2 years. 1. “Eucarbon” is an active remedy for the Diseases: Diagnosis and Dosage:
The distribution of diseases was as follows: The diagnosis was established (based) on 15 patients were with irritable colon syn-
endoscopies and clinical examinations. The 2. The “Eucarbon” influence is equally effec-
drome, 10 patients with atonic constipation colonoscopy was carried out on 20 patients, tive for all forms of constipation in colon and 10 with spastic constipation.
diseases. The atonic constipation treatment
The “Eucarbon” dose was 2 tablets twice a is especially effective. The irritable colon
day – in the morning and in the evening. In syndrome and spastic constipation is also
some rare cases, on colon hypermotility, the influenced by “Eucarbon”, but the optimal
tion (defecation 1 – 2 times a week) and dose was reduced to 1 tablet twice a day. The result was achieved after addition of sedative the symptoms connected with constipation: drug was given during a period of 12 weeks, and spasmolytic drugs. meteorism, abdominal pain, sometimes
the average distribution was 20 tablets a
cramps in hypogastrium, incomplete sensa-
3. The curative dose of „Eucarbon“ is 2 – 4
tion of evacuation, the imperative demand
of defecation etc. Diarrhea was not present. Results Our purpose was to investigate the influence After termination of the examination we can 4. The “Eucarbon” therapy was character- of “Eucarbon” in the clinical cases with con-
stipation. The minimum duration of preceding consti-
• The abdominal pain intensity (diffuse 5. It is expedient to use “Eucarbon” for the
pation was 5 years – the maximum 18 years. or spastic pain) sharply diminished. After 2 treatment of various forms of constipation Before the medication with “Eucarbon” the weeks of treatment the pain completely dis-
ments: Senada, Senadexin, Duspatalin, • The meteorism also mainly decreased, Laxena. Sometimes it was necessary to give especially at the end of the investigation. clysters.
• The accompanying diseases and their intensity did not change under the influence
The accompanying diseases were: in 16 • The most important outcome was that patients – chronic chiolecystitis, in 5 patients “Eucarbon” treatment changes and trans-
– peptic ulcer, in 7 – chronic gastritis, in
forms the rhythm of evacuation. From the
2 – arterial hypertension II, in 1 patient fifth day of treatment on there was a ten-
– heart failure I, in 2 patients – obesity III, dency of colon transit regulation and after N. Kekelidzein 1 patient – neurasthenia and in 1 patient 2 weeks the transit was entirely regulated.
– neurotic depression. The accompanying
The excrement consistence was stable, only M. Mamulashvili
diseases had already been present during in spastic colitis it showed small spastic
10 – 15 years, that means they had been particles. After antispasmodic and sedative ment in Tiflis/ Georgia. running parallel with the main syndrome therapy (Librax, Duspatalin) this spasm was (constipation). For the correction of the completely reduced. accompanying diseases the patients were No serious adverse effects were noticed dur-given drugs like: Flamin, Phosphalugel, ing treatment.
Vol. 20, SEPTEMBER 2003 - MODERN MEDICINE 1
The Glaucoma Service Foundation to Prevent Blindness GLAUCOMA SERVICE STAFF AT WILLS EYE INSTITUTE Mary Jude Cox, MD • Eugene Fernandes, MD • Scott Fudemberg, MD • L. Jay Katz, MD • Marlene R. Moster, MD • Jonathan S. Myers, MDRachel Niknam, MD • Joseph Ortiz, MD • Michael J. Pro, MD • Courtland Schmidt, MD • Geoffrey Schwartz, MDLouis W. Schwartz, MD • George L. Spaet